New surfactant for preterm babies with respiratory distress syndrome: a first-in-human study

What’s the safety and tolerability of the new enriched synthetic surfactant CHF5633? Associate Editor of ADC FN Jonathan Davis is joined by David Sweet (Royal Maternity Hospital, Belfast) to discuss a first-in-human clinical study of two human surfactant proteins in preterm babies with respiratory distress syndrome.

Read the Archives of Disease in Childhood: Fetal & Neonatal's open access paper "A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome": http://fn.bmj.com/content/102/6/F497.